Spruce Biosciences, Inc. (SPRB) stock
SPRBNasdaqPharmaceutical PreparationsFiscal year ends December 31
$40.49−1.76 (-4.17%)
Close on Nov 17, 2026Market cap $116.37MP/E –Yield –
Spruce Biosciences operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Spruce Biosciences's operating cash flow for the twelve months ending Jun 30, 2026 was -$42.62M. For fiscal 2025 it was -$33.33M. The highest annual figure on record is -$12.62M in fiscal 2019.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$33.33M | – |
| FY2024 | Dec 31, 2024 | -$55.96M | – |
| FY2023 | Dec 31, 2023 | -$33.28M | – |
| FY2022 | Dec 31, 2022 | -$41.68M | – |
| FY2021 | Dec 31, 2021 | -$35.88M | – |
| FY2020 | Dec 31, 2020 | -$27.52M | – |
| FY2019 | Dec 31, 2019 | -$12.62M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$22.12M | – |
| Q1 FY2026 | Mar 31, 2026 | -$8.73M | – |
| Q4 FY2025 | Dec 31, 2025 | -$6.46M | – |
| Q3 FY2025 | Sep 30, 2025 | -$5.32M | – |
| Q2 FY2025 | Jun 30, 2025 | -$8.83M | – |
| Q1 FY2025 | Mar 31, 2025 | -$12.73M | – |
| Q4 FY2024 | Dec 31, 2024 | -$20.68M | – |
| Q3 FY2024 | Sep 30, 2024 | -$9.22M | – |
| Q2 FY2024 | Jun 30, 2024 | -$11.11M | -657.3% |
| Q1 FY2024 | Mar 31, 2024 | -$14.96M | – |
| Q4 FY2023 | Dec 31, 2023 | -$11.21M | – |
| Q3 FY2023 | Sep 30, 2023 | -$12.27M | – |
| Q2 FY2023 | Jun 30, 2023 | $1.99M | – |
| Q1 FY2023 | Mar 31, 2023 | -$11.79M | – |
| Q4 FY2022 | Dec 31, 2022 | -$11.74M | – |
| Q3 FY2022 | Sep 30, 2022 | -$8.58M | – |
| Q2 FY2022 | Jun 30, 2022 | -$9.54M | – |
| Q1 FY2022 | Mar 31, 2022 | -$11.83M | – |
| Q4 FY2021 | Dec 31, 2021 | -$9.80M | – |
| Q3 FY2021 | Sep 30, 2021 | -$7.60M | – |
| Q2 FY2021 | Jun 30, 2021 | -$9.69M | – |
| Q1 FY2021 | Mar 31, 2021 | -$8.79M | – |
| Q4 FY2020 | Dec 31, 2020 | -$9.27M | – |
| Q3 FY2020 | Sep 30, 2020 | -$7.60M | – |
| Q2 FY2020 | Jun 30, 2020 | -$4.70M | – |
| Q1 FY2020 | Mar 31, 2020 | -$5.96M | – |
| Q4 FY2019 | Dec 31, 2019 | -$2.91M | – |
See a number that looks wrong?